Ascendis Pharma and Novo Nordisk Sign Collaboration for …
Nov 4, 2024 · - Collaboration leverages Ascendis’ proprietary TransCon ™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate. COPENHAGEN, Denmark, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has granted Novo Nordisk A/S an exclusive worldwide ...
Ascendis Pharma and Novo Nordisk Join Forces - Yahoo Finance
Nov 4, 2024 · Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon technology, aiming to develop treatments for metabolic and ...
News Releases - Ascendis Pharma
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024. November 4, 2024. Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases. September 30, 2024.
After 2 delays over 15 months, FDA approves Ascendis' Yorvipath
Aug 12, 2024 · After two delays, the FDA has signed off on Ascendis' Yorvipath, which is the first approved product for hypoparathyroidism in adults in the US.
Ascendis Pharma Presents New Data and Updated Results from …
ASND. - 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γin combination with TransCon TLR7/8 ...
Ascendis Pharma to Report Third Quarter 2024 Financial Results
5 days ago · --Ascendis Pharma A/S today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets.
Ascendis Pharma Reports Full Year 2022 Results
Feb 16, 2023 · Full-Year 2022 Financial Results. Total revenue for 2022 was €51.2 million compared to €7.8 million in 2021. Revenue for 2022 include SKYTROFA U.S. revenue, and license, clinical supply and services provided to third parties, primarily VISEN Pharmaceuticals.
Ascendis Pharma and Novo Nordisk Sign Collaboration for …
COPENHAGEN, Denmark, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in ...
Ascendis Pharma’s stock rises after FDA approval for first and only ...
Aug 12, 2024 · The stock of Ascendis Pharma A/S jumped 4.5% Monday, after the biotech said the U.S. Food and Drug Administration has approved its Yorvipath as the first and only treatment for a rare endocrine...
Ascendis Pharma to Report Third Quarter 2024 Financial
5 days ago · The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/S
- Some results have been removed